Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
(Dexborneol + edaravone) by Simcere Pharmaceutical Group for Acute Ischemic Stroke: Likelihood of Approval
(Dexborneol + edaravone) is under clinical development by Simcere Pharmaceutical Group and currently in Phase I for Acute Ischemic Stroke....
Data Insights
(Dexborneol + edaravone) by Neurodawn Pharmaceutical for Acute Ischemic Stroke: Likelihood of Approval
(Dexborneol + edaravone) is under clinical development by Neurodawn Pharmaceutical and currently in Phase I for Acute Ischemic Stroke. According...